The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

According to a news release Monday, the KFC Yum! Center added six water refill stations that includes a message about the quality of Louisville's drinking water. The new initiative allows guests ...

Beginning on Monday, customers who order a “for here” beverage can get free refills of hot or iced coffee, or hot or iced tea, during their visit. Baristas will serve up these orders in coffee ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor agonist semaglutide in adults with obesity. The phase 3b STEP UP trial has been ...

WASHINGTON — (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been ... “Some folks have to skip a dose in their prescription so they can make a prescription last ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.